Mirificin
Based on 1 Customer Validation
Mirificin (Puerarin apioside) is a blood-brain barrier-permeable tyrosinase inhibitor, with an IC50 value of 12.66 μM against mushroom tyrosinase. Mirificin reduces the expression of ALOX12 in cardiomyocytes and alleviates hypoxia/reoxygenation-induced apoptosis. The neuroprotective effect of Mirificin depends on the activation of VEGFR2 and HSP1A1, which reduces cerebral infarct size and improves neurological function. Mirificin can be used in the research of hyperpigmentation, acute myocardial infarction and ischemic stroke.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 99.66%
- CAS 番号: 103654-50-8
- 分子式: C26H28O13
- 分子量:548.49
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
HY-N0192
Arbutin
-
HY-N0616
Trifolirhizin
-
HY-107369
4-Butylresorcinol
-
HY-N0192R
Arbutin (Standard)
-
HY-W003607
3-O-Ethyl-L-ascorbic acid
-
HY-N1775
3',4'-Dihydroxyacetophenone
-
HY-N3266
Methyl rosmarinate
-
HY-N3518
Mulberroside F
-
HY-101445A
(R)-Trolox
-
HY-N10503
Norartocarpetin
-
HY-113068
(rel)-β-Tocopherol
-
HY-N2204
Swertiajaponin
VEGFR アイソフォーム固有の製品をすべて表示
More
生物活性
|
12-LOX |
VEGFR-2 |
HSP1A1 |
Mirificin (20.0 μM) shows no toxicity to H9c2 rat cardiomyocytes, even at the highest concentration tested[2].
Mirificin (5-50 μM; 24 h) dose-dependently increases the viability and reduces the cytotoxicity of differentiated PC12 cells with oxygen-glucose deprivation/reperfusion (OGD/R) injury[3].
Mirificin (0.1-10.0 μM) significantly reduces the mRNA expression level of Alox12 in H9c2 rat cardiomyocytes[2].
Mirificin (0.1 μM; 3 h) protects H9c2 rat cardiomyocytes against hypoxia/reoxygenation (H/R)-induced injury by inhibiting ALOX12 protein expression, restoring the BCL-2/BAX ratio, and reducing apoptosis[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Alox12-silenced H9c2 rat cardiomyocytes
-
Concentration:0.1 μM
-
Incubation Time:3 h (pretreatment prior to H/R)
-
Result:Produced no significant change in the apoptotic cell ratio compared to the H/R + siAlox12 control group.
-
Cell Line:OGD/R-injured differentiated PC12 cells
-
Concentration:5; 20; 50 μM
-
Incubation Time:24 h (pre-incubated prior to OGD/R)
-
Result:Increased cell viability to 65.8% at 5 μmol/L.
Increased cell viability to 67.4% at 20 μmol/L.
Increased cell viability to 69.5% at 50 μmol/L.
Reduced LDH leakage to 83.3% at 5 μmol/L.
Reduced LDH leakage to 84.8% at 20 μmol/L.
Reduced LDH leakage to 70.5% at 50 μmol/L.
Mirificin (12.5-25 mg/kg; i.p.; two administrations) reduces the cerebral infarction volume and improves neurological function in mice with ischemic stroke induced by middle cerebral artery occlusion (MCAO)[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (male, 6 weeks old, 18-22g, intraluminal middle cerebral artery occlusion with 2 hours of occlusion followed by reperfusion)[3]
-
Dosage:12.5 mg/kg; 25 mg/kg
-
Administration:i.p.; two time points (1 hour pre-MCAO and 1 hour post-MCAO)
-
Result:Showed a significant reduction in Longa's Neurological Severity Score and a significant decrease in cerebral infarct area at 12.5 mg/kg.
Showed significant reductions in both neurological deficit score and cerebral infarct area, with a larger reduction in infarct area than the 12.5 mg/kg group at 25 mg/kg.
化学情報
-
CAS 番号 103654-50-8
-
性状 Solid
-
分子量 548.49
-
分子式 C26H28O13
-
Color White to light yellow
-
SMILES
OC1=CC=C2C(OC=C(C3=CC=C(O)C=C3)C2=O)=C1[C@@H]([C@@H]([C@@H](O)[C@@H]4O)O)O[C@@H]4CO[C@H](OC[C@]5(O)CO)[C@@H]5O
-
別名
Puerarin apioside; ミリフィシン
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
純度とドキュメンテーション
-
データシート (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
[1]. Liu H, et al. Enzyme-Site Blocking Combined with Optimization of Molecular Docking for Efficient Discovery of Potential Tyrosinase Specific Inhibitors from Puerariae lobatae Radix. Molecules. 2018 Oct 11;23(10):2612. [Content Brief]
[2]. Xing H, et al. The potential effective components from Danlou tablet attenuates acute myocardial infarction by restoring ALOX12-mediated perturbed oxylipins. Journal of ethnopharmacology. 2025 Apr 09;345:119617. [Content Brief]
[3]. Zhou Z, et al. Integrating UHPLC-MS, Network Pharmacology, and Molecular Docking techniques to explore the neuroprotective effect of Mirificin. Naunyn-Schmiedeberg's archives of pharmacology. 2026 Feb;399(4):5447-5462. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Mirificin 関連分類
HY-N2134 関連分類
Powered by Bioz